BioCentury | Feb 13, 2021
Deals

Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare

...By Jeff Cranmer, Executive Editor Shares of NexImmune Inc. (NASDAQ:NEXI) and Decibel Therapeutics Inc. (NASDAQ:DBTX) traded higher Friday...
...while immunotherapy play NexImmune raised $110 million through the sale of 6.5 million shares at $17. NexImmune...
...initial enterprise value of $3.9 billion with about $400 million in capital. Jeff Cranmer Forbion Capital Partners Decibel Therapeutics NexImmune Sagimet...
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune...
...Roads, General Atlantic, GP Healthcare Capital, Sequoia Capital China and Wuxi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359).NexImmune Inc.’s...
...cell-mediated immune responses.A syndicate led by former Celgene Corp. Chairman and CEO Sol Barer acquired NexImmune...
BioCentury | Jan 20, 2021
Management Tracks

Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune

...manufacturing officer. McCubbin was head of technical operations at Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE).Immunotherapy play NexImmune Inc. hired Robert...
...officer; and separately appointed Grant Verstandig, chief digital officer at UnitedHealth Group Inc. (NYSE:UNH), to its board. Before NexImmune...
...Inc. T-knife GmbH Audentes Therapeutics Inc. Astellas Pharma Inc. Applied Molecular Transport Inc. Unity Biotechnology Inc. Frequency Therapeutics Inc. Cerevel Therapeutics Holdings Inc. NexImmune Inc. UnitedHealth...
BioCentury | Jan 16, 2021
Management Tracks

FDA’s Schiller joins Aetion; plus Novavax, NHC, NextCure, Ziopharm, ONK

...NASDAQ:NXTC) hired Han Myint as chief medical officer. Before joining NextCure, Myint was CMO of immunotherapy company NexImmune Inc....
BioCentury | Jan 5, 2018
Financial News

NexImmune raises $23M series A

...hematopoietic stem cell (HSC) transplant. AIM ACT is a CD8 T cell-activating therapy based on NexImmune’s...
...dysfunctional or absent natural antigen-presenting cells with artificial antigen-presenting cells that direct specific immune responses. NexImmune...
...see BioCentury, Feb. 17, 2017 ). NexImmune Inc., Gaithersburg, Md. Elizabeth S. Eaton AIM ACT Celgene Corp. Johns Hopkins University Medtronic plc NexImmune Inc. CD8...
BioCentury | Jan 2, 2018
Financial News

NexImmune raises $23M series A

...hematopoietic stem cell (HSC) transplant. AIM ACT is a CD8 T cell-activating therapy based on NexImmune’s...
...dysfunctional or absent natural antigen-presenting cells with artificial antigen-presenting cells that direct specific immune responses. NexImmune...
...CEO Sol Barer, his son Joshua, and former Medtronic plc (NYSE:MDT) CEO William Hawkins acquired NexImmune...
BioCentury | Feb 17, 2017
Finance

NexImmune’s next act

...about what product to develop first was the catalyst for the sale of immuno-oncology play NexImmune Inc....
...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). On Feb. 14, the new syndicate acquired all NexImmune...
...Investments for an undisclosed sum. The new investor group also put additional undisclosed capital in NexImmune...
BioCentury | Feb 16, 2017
Company News

NexImmune deal

...An investor group acquired immuno-oncology company NexImmune for an undisclosed amount. The group includes Sol Barer...
...who was chairman and CEO of Medtronic plc (NYSE:MDT, Dublin, Ireland); and other undisclosed investors NexImmune...
...the investment but are no longer represented. NexImmune Inc. , Gaithersburg, Md. Business: Cancer Jaime De Leon AIM ACT NexImmune Inc....
BioCentury | Feb 14, 2017
Financial News

Barer among investors acquiring NexImmune

...including former CEOs of Celgene Corp. (NASDAQ:CELG) and Medtronic plc (NYSE:MDT) has acquired immuno-oncology company NexImmune Inc....
...undisclosed investors. Sol Barer became Teva's chairman last week (see BioCentury Extra, Feb. 6) . NexImmune...
...treat hematological malignancies. The candidate is a CD8 T cell-activating adoptive cellular therapy based on NexImmune’s...
BioCentury | Jul 28, 2014
Financial News

NexImmune completes venture financing

NexImmune Inc. , Gaithersburg, Md. Business: Cancer Date completed: 2014-07-17 Type: Venture financing Raised: $3 million Investors: New Enterprise Associates; Pfizer Venture Investments; Amgen Ventures WIR Staff...
Items per page:
1 - 10 of 14
BioCentury | Feb 13, 2021
Deals

Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare

...By Jeff Cranmer, Executive Editor Shares of NexImmune Inc. (NASDAQ:NEXI) and Decibel Therapeutics Inc. (NASDAQ:DBTX) traded higher Friday...
...while immunotherapy play NexImmune raised $110 million through the sale of 6.5 million shares at $17. NexImmune...
...initial enterprise value of $3.9 billion with about $400 million in capital. Jeff Cranmer Forbion Capital Partners Decibel Therapeutics NexImmune Sagimet...
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune...
...Roads, General Atlantic, GP Healthcare Capital, Sequoia Capital China and Wuxi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359).NexImmune Inc.’s...
...cell-mediated immune responses.A syndicate led by former Celgene Corp. Chairman and CEO Sol Barer acquired NexImmune...
BioCentury | Jan 20, 2021
Management Tracks

Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune

...manufacturing officer. McCubbin was head of technical operations at Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE).Immunotherapy play NexImmune Inc. hired Robert...
...officer; and separately appointed Grant Verstandig, chief digital officer at UnitedHealth Group Inc. (NYSE:UNH), to its board. Before NexImmune...
...Inc. T-knife GmbH Audentes Therapeutics Inc. Astellas Pharma Inc. Applied Molecular Transport Inc. Unity Biotechnology Inc. Frequency Therapeutics Inc. Cerevel Therapeutics Holdings Inc. NexImmune Inc. UnitedHealth...
BioCentury | Jan 16, 2021
Management Tracks

FDA’s Schiller joins Aetion; plus Novavax, NHC, NextCure, Ziopharm, ONK

...NASDAQ:NXTC) hired Han Myint as chief medical officer. Before joining NextCure, Myint was CMO of immunotherapy company NexImmune Inc....
BioCentury | Jan 5, 2018
Financial News

NexImmune raises $23M series A

...hematopoietic stem cell (HSC) transplant. AIM ACT is a CD8 T cell-activating therapy based on NexImmune’s...
...dysfunctional or absent natural antigen-presenting cells with artificial antigen-presenting cells that direct specific immune responses. NexImmune...
...see BioCentury, Feb. 17, 2017 ). NexImmune Inc., Gaithersburg, Md. Elizabeth S. Eaton AIM ACT Celgene Corp. Johns Hopkins University Medtronic plc NexImmune Inc. CD8...
BioCentury | Jan 2, 2018
Financial News

NexImmune raises $23M series A

...hematopoietic stem cell (HSC) transplant. AIM ACT is a CD8 T cell-activating therapy based on NexImmune’s...
...dysfunctional or absent natural antigen-presenting cells with artificial antigen-presenting cells that direct specific immune responses. NexImmune...
...CEO Sol Barer, his son Joshua, and former Medtronic plc (NYSE:MDT) CEO William Hawkins acquired NexImmune...
BioCentury | Feb 17, 2017
Finance

NexImmune’s next act

...about what product to develop first was the catalyst for the sale of immuno-oncology play NexImmune Inc....
...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). On Feb. 14, the new syndicate acquired all NexImmune...
...Investments for an undisclosed sum. The new investor group also put additional undisclosed capital in NexImmune...
BioCentury | Feb 16, 2017
Company News

NexImmune deal

...An investor group acquired immuno-oncology company NexImmune for an undisclosed amount. The group includes Sol Barer...
...who was chairman and CEO of Medtronic plc (NYSE:MDT, Dublin, Ireland); and other undisclosed investors NexImmune...
...the investment but are no longer represented. NexImmune Inc. , Gaithersburg, Md. Business: Cancer Jaime De Leon AIM ACT NexImmune Inc....
BioCentury | Feb 14, 2017
Financial News

Barer among investors acquiring NexImmune

...including former CEOs of Celgene Corp. (NASDAQ:CELG) and Medtronic plc (NYSE:MDT) has acquired immuno-oncology company NexImmune Inc....
...undisclosed investors. Sol Barer became Teva's chairman last week (see BioCentury Extra, Feb. 6) . NexImmune...
...treat hematological malignancies. The candidate is a CD8 T cell-activating adoptive cellular therapy based on NexImmune’s...
BioCentury | Jul 28, 2014
Financial News

NexImmune completes venture financing

NexImmune Inc. , Gaithersburg, Md. Business: Cancer Date completed: 2014-07-17 Type: Venture financing Raised: $3 million Investors: New Enterprise Associates; Pfizer Venture Investments; Amgen Ventures WIR Staff...
Items per page:
1 - 10 of 14